In the North American pharmaceutical industry, there were 213 M&A deals announced in Q2 2024, worth a total value of $23bn, according to GlobalData’s Deals Database. The $4.9bn acquisition of Alpine Immune Sciences by Vertex Pharmaceuticals was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q2 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in North America decreased by 53% in Q2 2024 compared with the previous quarter’s total of $49.3bn and fell by 41% as compared to Q2 2023. Related deal volume decreased by 7% in Q2 2024 versus the previous quarter and was 23% lower than in Q2 2023.
The top-ranked financial advisors supporting these M&A deals in North America in H1 2024 were Centerview Partners; Goldman Sachs Group; Lazard with 8, 7, 7 deals respectively.
The top-ranked legal advisors supporting these M&A deals in North America in H1 2024 were Goodwin Procter; Kirkland & Ellis; Cooley with 14, 11, 9 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2024 – Thematic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.